HemaSpot provides a capillary self-sampling device that allows patients to collect blood samples at home, eliminating the need for clinic visits and ensuring high sample integrity. Their CLIA-certified laboratory offers over 80 analytical tests with up to 97% accuracy, streamlining the diagnostic process and enhancing patient care in telehealth settings.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional blood sample collection requires in-person clinic visits, which can be inconvenient for patients, especially those with mobility issues or those residing in remote areas. This reliance on clinic-based sampling can lead to delays in diagnosis and monitoring, hindering timely medical intervention.
Solution
HemaSpot offers a capillary self-sampling device that enables patients to conveniently collect blood samples at home, eliminating the need for clinic visits. The device is designed for ease of use and ensures high sample integrity. Samples are then sent to their CLIA-certified laboratory, which specializes in microsampling and offers over 80 analytical tests with up to 97% accuracy. This streamlined process enhances patient care in telehealth settings by providing accurate and timely results.
Target Audience
The primary target audience includes telehealth providers and healthcare organizations seeking to offer convenient and reliable at-home blood sample collection and analysis to their patients.
Features
- Capillary self-sampling device designed for virtually painless blood collection at home
- CLIA-certified laboratory specializing in microsampling
- Over 80 analytical tests available
- Up to 97% accuracy in test results
- Custom white-label solutions designed for seamless integration into telehealth platforms
- Vertical integration managing every step of the testing process from device design to analysis